Abiopharma

🔍 Rinsky Jason (Executive)

Company: Leonardo DRS, Inc. (DRS)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 17,316 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 29,631.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,414 shares of Common Stock at $45.86 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 23,217.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 11,608 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 34,825.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 5,717 shares of Common Stock at $45.86 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 29,108.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 5,375 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 34,483.00 | transaction_form_type: 4
• Sold 2,648 shares of Common Stock at $45.86 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 31,835.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 3,795 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 35,630.00 | transaction_form_type: 4
• Sold 1,870 shares of Common Stock at $45.86 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 33,760.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,789 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 36,549.00 | transaction_form_type: 4
• Sold 1,374 shares of Common Stock at $45.86 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 35,175.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 5,375 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F4, F4
• Sold 3,795 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,795.00 | transaction_form_type: 4 | Footnotes: F5, F5, F5
• Sold 2,789 shares of Restricted Stock Unit (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,578.00 | transaction_form_type: 4 | Footnotes: F6, F6, F6

Footnotes:

• F1: Represents performance restricted stock units ("PRSUs") awarded in April 2023 under the Issuer's 2022 Omnibus Equity Compensation Plan (the "Plan") for the performance period January 1, 2023 through December 31, 2025, for which performance goals have been achieved and certified on February 19, 2026. Each PRSU represents the right to one share of the Issuer's common stock. The PRSUs vested on April 1, 2026.
• F2: Shares withheld by the Issuer to satisfy tax withholding requirements.
• F3: Represents PRSUs awarded in April 2023 under the Plan for the performance period January 1, 2023 through December 31, 2025, for which performance goals have been achieved and certified on February 19, 2026. Each PRSU represents the right to one share of the Issuer's common stock. The PRSUs vested on April 1, 2026.
• F4: Each restricted stock unit ("RSU") was granted under the Plan, and represents a contingent right to receive one share of the common stock of the Issuer or the cash equivalent thereof. One-third of the RSUs vested on April 1, 2024 and April 1, 2025. The remaining RSUs vested on April 1, 2026.
• F5: Each RSU was granted under the Plan, and represents a contingent right to receive one share of the common stock of the Issuer or the cash equivalent thereof. One-third of the RSUs vested on each of April 1, 2025 and April 1, 2026. The remaining one-third of RSUs are scheduled to vest on April 1, 2027, subject to the Reporting Person's continued employment with the Issuer through such date.
• F6: Each RSU was granted under the Plan, and represents a contingent right to receive one share of the common stock of the Issuer or the cash equivalent thereof. One-third of the RSUs vested on April 1, 2026. The remaining RSUs are scheduled to vest one-third annually on each of April 1, 2027 and April 1, 2028, subject to the Reporting Person's continued employment with the Issuer through each date.